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Moderate Renal Insufficiency
Does Not Attenuate the
Clinical Benefit of Aldosterone
Antagonists in Heart Failure*
Michael S. Kiernan, MD, Marvin A. Konstam, MD
Boston, Massachusetts
Clinical trials of aldosterone antagonists (AAs) have estab-
lished substantial reductions in mortality when added to
background therapy in patients with heart failure (HF) and
reduced left ventricular ejection fraction (LVEF) (1,2).
Although use of AAs has increased over time, it remains less
than expected, on the basis of the results of clinical trials and
clinical practice guideline recommendations (3). Chronic
kidney disease (CKD) is common among patients with HF
and is independently associated with increased morbidity
and mortality (4). Several studies demonstrate that, despite
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the higher risk in this population, history of CKD is
associated with underuse of evidence-based therapies (3,5).
The paradoxical decline in the use of effective therapies
among these higher-risk patients might be partially ex-
plained by: 1) the exclusion of patients with significant CKD
from many clinical trials; and 2) the increased risk of adverse
events among patients with CKD (3). The increased mor-
bidity of CKD in patients with HF is therefore likely to be
multi-factorial, with contributions from associated comor-
bidities, increased fluid retention, and underuse of effective
treatments (5).
Vardeny et al. (6) present data from RALES (Random-
ized Aldactone Evaluation Study) in this issue of the Journal
with regard to the use of AAs in patients with HF and
CKD. Although they confirm prior observations that base-
line CKD is associated with higher mortality, the primary
finding is that spironolactone retains its therapeutic efficacy
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Johnson and Johnson, Amgen, and GlaxoSmithKline.among patients with moderate CKD. Although baseline
CKD is associated with increased risk of adverse events, this
risk did not negate the overall net clinical benefit. These
data provide reassurance with regard to the relative safety
and net benefit of AAs among patients with HF, reduced
LVEF, and moderate CKD. Although the authors conclude
that the absolute benefit of spironolactone is greatest among
patients with reduced glomerular filtration rate (GFR), this
statement must be qualified, because patients with more
severe CKD (serum creatinine 2.5 mg/dl) were excluded
from the trial.
The authors hypothesize that the greater benefit of
spironolactone seen in patients with CKD might be related
to the ability of AAs to reduce renal injury; however, a
beneficial effect of AAs on GFR in patients with CKD has
not been demonstrated (7). A major health risk for patients
with CKD is an increased risk of death from cardiovascular
causes. Elevated levels of aldosterone are seen in CKD and
might impair ventricular and vascular function via pro-
inflammatory and pro-fibrotic pathways (8). Although data
with regard to the ability of AAs to improve myocardial
remodeling are mixed, these agents have shown favorable
effects on interstitial collagen turnover and cardiac fibrosis
(9,10). Among patients with CKD, AAs have also been
demonstrated to improve arterial stiffness, vascular tone, and
function, independent of their effect on blood pressure
(11,12). It seems that the benefit of AA among patients
with co-existing CKD and HF is more likely related to their
beneficial effect on the heart and vasculature.
Vardeny et al. (6) confirm reports that worsening renal
function (WRF) in patients with HF is a marker of poor
long-term outcomes. However, similar to findings with
enalapril within SOLVD (Studies of Left Ventricular Dys-
function) (13), there was a significant interaction between
the treatment group and WRF with respect to outcome.
WRF was associated with increased mortality only among
patients randomized to placebo, whereas patients taking
spironolactone derived benefit, independent of WRF. An
explanation for this finding is that WRF in patients with
HF signals a heterogeneous set of physiologic effects, with
distinct mechanisms and prognostic implications (13). The
anticipated decrease in filtration fraction after angiotensin
converting enzyme inhibitor initiation represents a marker
of therapeutic efficacy and does not carry an adverse prog-
nosis (13). The mechanism by which AAs lead to WRF is
unknown. The authors hypothesize the reduction in GFR
might be the result of reduction in blood pressure affecting
renal blood flow. However, differences in blood pressure
between groups at the end of titration did not exist, and
patients taking spironolactone had higher rates of WRF.
In contrast to the present report, WRF after eplerenone
initiation in patients with HF and/or reduced LVEF after
myocardial infarction is associated with worse outcomes
(14), and the prognostic implication of WRF short-term
after AA initiation remains uncertain. A total of 117 early
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and patients who died early were not included in the
landmark analysis (6). WRF occurred in 17% of patients
taking spironolactone, compared with 7% of patients taking
placebo (p  0.001); the greatest risk of hyperkalemia
ccurred in patients with WRF taking spironolactone:
2.4% versus 6.8% for patients with stable renal function
andomized to placebo. Therefore it is not possible to
ismiss a significant early risk of death associated with
RF among patients taking spironolactone. Although an
ssociation between hyperkalemia and risk of death is not
resented, an analysis from the HEAAL (Heart Failure
nd Point Evaluation of Angiotensin II Antagonist Losar-
an) study demonstrated that, for patients receiving angio-
ensin receptor blockers, rates of hyperkalemia increase
mong patients also receiving AAs, and these events are
ssociated with an increased risk of dying (15).
In conclusion, baseline renal function does not attenuate
he 30% relative risk reduction of mortality seen with AAs
n patients with HF and reduced LVEF. Although risks of
As, including that of hyperkalemia in patients with CKD,
ust continue to be considered, the present analysis should
erve to promote use of AAs, under careful monitoring,
mong patients with mild to moderate CKD and should
ead to increased use of this life-prolonging therapy. Al-
hough abnormal and worsening kidney function are asso-
iated with worse prognosis in patients with HF, the
echanistic inter-relationships among clinical HF, kidney
unction, and morbid events are complex. Improved under-
tanding of these interactions will increase our ability to
pply available HF treatments toward achieving improving
linical outcomes.
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